Protagonist Therapeutics, Inc (PTGX): Revenue
$46.02M
Year ended 2025-12-31
$281.99M
Trailing 12 months to 2026-06-30
+20.1%
3-year compound annual growth
+10.0%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $46.02M | -89.4% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $434.43M | +624.1% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $60.00M | +125.7% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $26.58M | -2.8% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $27.36M | -4.4% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $28.63M | n/m | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $231.0K | -99.3% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $30.93M | +54.1% | 2019-03-12, From 2018-01-01 |
| 2017-12-31 | $20.06M | n/a | 2019-03-12, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $46.02M | -89.4% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $45.95M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $44.55M | -22.6% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $44.52M | +17.6% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $43.87M | -19.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $43.77M | +589.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $48.47M | -57.7% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $42.73M | -60.5% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $49.80M | +60.2% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗